The boy had received the therapy for Duchenne muscular dystrophy in a trial for boys aged 2 or 3. Pfizer is pausing its trial in older boys.
Advertisement
STAT+
Your go-to source for the world of life sciences, medicine, and biopharma. Subscribe now.Cancel anytime.
Subscribe nowMore From STAT
More From STAT
More From STAT
From policy to practice: STAT's podcasts decode health care complexities.
All PodcastsMore From STAT
More From STAT
More From STAT
We create tools to help you understand and track complex areas of development.
All Trackers
Here are the dozens of weight loss drugs in development to catch a booming market.
Follow the latest developments in genome editing.
A guide to the health systems and companies driving adoption.
An authoritative database of FDA’s fast-tracked medical devices.
More From STAT
More From STAT
More From STAT
STAT Reports blend data insights with qualitative observations on pivotal life sciences topics.
All Reports
$49
Our bestselling report is now updated to help you read clinical trial results with an appropriately skeptical (or critical) eye.
A new generation of drugs is transforming the way scientists think about the illness.
Interpreting clinical trial results is not for the faint of heart…
More From STAT
More From STAT
More From STAT
STAT offers a variety of in-person and virtual events throughout the year.
All Events
16
May
San Francisco, CA May 16, 2024
A one-day event focused on 'Medicine’s future, now' — where we'll explore opportunities and the latest advancements in medical science and technology.
Mon - Fri
Your daily dose of news in health and science
Our Picks
Our Picks
STAT’s selection of must-read stories and investigations
War on Recovery
War on Recovery
